盘前交易概况 - 美东时间周四上午7:35盘前交易出现显著活跃 多只股票呈现价格异动[1] - 盘前价格变动可能预示开盘后潜在交易机会 包括突破、反转或剧烈波动[1] - 早盘动量通常延续至常规交易时段 使盘前分析成为交易日关键组成部分[1] 涨幅显著股票 - PepGen Inc (PEPG) 股价上涨151%至6.68美元 位列涨幅榜首[3] - 22nd Century Group Inc (XXII) 上涨27%至1.93美元 涨幅排名第二[3] - Immuneering Corporation (IMRX) 上涨23%至11.36美元 位列涨幅第三[3] - uniQure N.V. (QURE) 上涨10%至52.58美元 锂业公司Lithium Americas Corp (LAC)同步上涨9%至6.60美元[3] - Jasper Therapeutics Inc (JSPR) 上涨9%至2.55美元 American Shared Hospital Services (AMS) 上涨8%至2.75美元[3] - PSQ Holdings Inc (PSQH) 上涨7%至3.06美元 K Wave Media Ltd (KWM) 同步上涨7%至2.48美元[3] - ClearPoint Neuro Inc (CLPT) 上涨5%至20.48美元 跻身涨幅前十[3] 跌幅显著股票 - Transocean Ltd (RIG) 下跌14%至3.11美元 领跌盘前交易[4] - Cyclerion Therapeutics Inc (CYCN) 下跌12%至2.83美元 跌幅排名第二[4] - CarMax Inc (KMX) 下跌11%至50.38美元 ARB IOT Group Limited (ARBB) 同步下跌11%至10.45美元[4] - SHF Holdings Inc (SHFS) 下跌10%至6.49美元 Digital Brands Group Inc (DBGI) 同步下跌10%至6.21美元[4] - Aqua Metals Inc (AQMS) 下跌9%至5.29美元 Akanda Corp (AKAN) 下跌8%至3.96美元[4] - Galecto Inc (GLTO) 下跌8%至3.88美元 Platinum Analytics Cayman Limited (PLTS) 下跌7%至11.12美元[4]

公司诉讼事件 - 律师事务所Robbins LLP提醒投资者，一项集体诉讼已代表在2023年11月30日至2025年7月3日期间购买或收购Jasper Therapeutics, Inc (NASDAQ: JSPR) 证券的个人和实体提起 [1] - 诉讼指控公司未能披露其缺乏必要的控制和程序，以确保所依赖的第三方制造商完全按照cGMP法规生产产品并适用于临床试验 [2] - 诉讼指控上述失败增加了正在进行的研究结果被混淆的风险，从而对公司产品（包括briquilimab）的监管和商业前景产生负面影响 [2] - 诉讼指控上述情况增加了破坏性成本削减措施的可能性，因此公司的业务和/或财务前景以及briquilimab的临床和/或商业前景被夸大 [2] 市场反应 - 2025年7月7日真相披露后，Jasper Therapeutics股价每股下跌3.73美元，跌幅达55.1%，报收于每股3.04美元 [3] 公司业务 - Jasper Therapeutics是一家临床阶段生物技术公司，专注于开发针对肥大细胞驱动疾病的疗法，如慢性自发性荨麻疹（CSU）、慢性诱导性荨麻疹（CIndU）和哮喘 [1] - 诉讼涉及公司的主要产品候选药物Briquilimab的商业前景 [2]

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025, inclusive (the "Class Period†). Jasper investors have until November 18, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN JASPER THERAPEUTICS, INC. (JSPR), CONTACT THE LAW OFFICES OF HOWA. ...

LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Jasper Therapeutics, Inc. (JSPR) Investors To Inquire About Securities Fraud Class Action. ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc.  (“Jasper” or the “Company”) (NASDAQ: JSPR) and certain officers.   The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-08010, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Jasper securities between November 30, 2023 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Jasper To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 Â (Ext. 1310). [You may also click here for additional information] NEW YORK , Sept. ...

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Jasper Therapeutics, Inc.  (“Jasper” or the “Company”) (NASDAQ: JSPR) and certain officers.  The class action, filed in the United States District Court for the Northern District of California, and docketed under 25-cv-08010, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Jasper securities between November 30, 2023 ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Jasper (JSPR) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Jasper between November 30, 2023 and July 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bra ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON JASPER THERAPEUTICS, INC. (JSPR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happen. ...

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Jasper Therapeutics, Inc. ("Jasper†or the "Company†) (NASDAQ: JSPR) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN JASPER THERAPEUTICS, INC. (JSPR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal. ...